34 Recruiting Recurrent Diffuse Large B-Cell Lymphoma Clinical Trials
Explore open interventional and observational research studies actively enrolling participants across the USA. Verify eligibility and contact site coordinators directly.
📍 Find Near Me by DistanceBrowse by State
Browse by Study Phase
Top Interventions for Recurrent Diffuse Large B-Cell Lymphoma
Related Conditions
Top Recruiting Recurrent Diffuse Large B-Cell Lymphoma Studies
Memory Enriched T Cells Following Stem Cell Transplant in Treating Patients With Recurrent B-Cell Non-Hodgkin Lymphoma
📍 City of Hope Medical Center — Duarte, California
View Study & Checklist ➔Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
📍 University of Chicago Comprehensive Cancer Center — Chicago, Illinois
View Study & Checklist ➔Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma
📍 M D Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma
📍 City of Hope Comprehensive Cancer Center — Duarte, California
View Study & Checklist ➔NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma
📍 Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington
View Study & Checklist ➔Lymphodepletion With Low Dose Total Body Irradiation Before Standard of Care Tisagenlecleucel for the Treatment of Relapsed and Recurrent Large B-cell Lymphoma
📍 Ohio State University Comprehensive Cancer Center — Columbus, Ohio
View Study & Checklist ➔Evaluation of Bridging Radiation Therapy Before CAR T-Cell Infusion for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma
📍 City of Hope Medical Center — Duarte, California
View Study & Checklist ➔Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
📍 University of Minnesota/Masonic Cancer Center — Minneapolis, Minnesota
View Study & Checklist ➔Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells
📍 City of Hope Medical Center — Duarte, California
View Study & Checklist ➔Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
📍 University of California Davis Comprehensive Cancer Center — Sacramento, California
View Study & Checklist ➔Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
📍 City of Hope Medical Center — Duarte, California
View Study & Checklist ➔Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy
📍 University of California Davis Comprehensive Cancer Center — Sacramento, California
View Study & Checklist ➔Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T
📍 Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington
View Study & Checklist ➔ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma
📍 Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington
View Study & Checklist ➔Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma
📍 University of California Davis Comprehensive Cancer Center — Sacramento, California
View Study & Checklist ➔